

Breast Cancer

Observational Study of Pertuzumab Safety in Participants With Breast Cancer

Trial Status Completed	Trial Runs In 1 Countries	Trial Identifier NCT02266173 ML29299
----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This Phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) will evaluate the safety of pertuzumab in approximately 1000 participants with metastatic or locally unresectable recurrent breast cancer who have never received chemotherapy or anti-human epidermal growth factor receptor 2 (HER2) therapy for their metastatic disease with HER2 positivity in Korea. Participants who are administered with pertuzumab according to medical opinions of the doctor in charge of surveillance will be registered for this study and treated with pertuzumab under the approval conditions of the product in Korea.

Hoffmann-La Roche Sponsor	N/A Phase
-------------------------------------	---------------------

NCT02266173 ML29299
Trial Identifiers

Eligibility Criteria:

Gender All	Age >= 18 Years	Healthy Volunteers No
----------------------	---------------------------	---------------------------------
